fbpx
No Result
View All Result
Nomad Africa Magazine | Celebrating the world's richest continent
  • Home
  • Tourism Updates
  • For Subscribers
  • Destinations
  • Culture
  • Get Published
  • More4U
    • Travel Tips
    • News Africa
    • Aviation
    • Special Features
    • Food+Wine
    • Showcase
    • Spotlight
    • Sponsored
    • Events
    • Tourism Data & Stats
    • Opinion
    • Survey/Polls
    • Watch
    • COVID19 Updates
  • Deals
    • Flights
    • Hotels
    • Tours
    • Shop
  • Login
SUBSCRIBE
Nomad Africa Magazine | Celebrating the world's richest continent
  • Home
  • Tourism Updates
  • For Subscribers
  • Destinations
  • Culture
  • Get Published
  • More4U
    • Travel Tips
    • News Africa
    • Aviation
    • Special Features
    • Food+Wine
    • Showcase
    • Spotlight
    • Sponsored
    • Events
    • Tourism Data & Stats
    • Opinion
    • Survey/Polls
    • Watch
    • COVID19 Updates
  • Deals
    • Flights
    • Hotels
    • Tours
    • Shop
  • Login
SUBSCRIBE
No Result
View All Result
Nomad Africa Magazine | Celebrating the world's richest continent
No Result
View All Result

Novartis renews WHO medicine donation pledge with aim of ending leprosy

Press Room by Press Room
in News
Reading Time: 3 mins read
0 0
0
Novartis renews WHO medicine donation pledge with aim of ending leprosy
Share on FacebookShare on Twitter
ADVERTISEMENT

Novartis (Novartis.com) leprosy medicine donation program with WHO extended to 2025; Program has already treated over 7 million patients since 2000; New evidence from contact tracing and preventive treatment program shows route to accelerate elimination.

A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.

Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year [1]. Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy.

By supplying this treatment free of charge to WHO over the last 20 years we have helped over seven million people be cured of leprosy

“Leprosy can be cured and prevented. With a comprehensive approach, we can see the end of leprosy,” said Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis. “By supplying this treatment free of charge to WHO over the last 20 years we have helped over seven million people be cured of leprosy. We look forward to helping increasingly few over the coming years.”

Novartis is working with WHO and the Global Partnership for Zero Leprosy – together with other stakeholders – to develop improved access to MDT globally. An additional future step seems certain to include the rollout of prophylaxis programs in affected countries. New evidence from a Novartis Foundation initiated operational research program [2] covering 170,000 people across seven countries has shown that giving prophylactic treatment with a single dose of a low-cost and widely available antibiotic to contacts of people diagnosed with leprosy is feasible, generally well accepted and is likely to have a key role in accelerating the elimination of the disease.

“WHO welcomes the extension of this long-standing partnership with Novartis. Multidrug therapy has been a cornerstone of the program to eliminate leprosy,” said Dr Ren Minghui, Assistant Director-General, Universal Health Coverage / Communicable and Noncommunicable Diseases, WHO. “We need to ensure we are reaching the last patients who are often in remote areas or informal settlements. It is in these deprived communities where much of the world’s remaining leprosy is concentrated.”

ADVERTISEMENT

The new agreement with WHO also covers the continuing donation of triclabendazole for the treatment of fascioliasis. This condition, more commonly known as liver fluke infestation, is a neglected tropical disease that infects 2.4 million people worldwide [3] with an additional 180 million at risk of infection [4]. Novartis has been donating the treatment to the WHO since 2005, helping to treat around two million fascioliasis patients in more than 30 countries. Triclabendazole is currently the only medicine for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines. It is supplied by WHO during epidemic outbreaks and for periodic use in endemic countries.

For over 30 years, Novartis and the Novartis Foundation have been working with partners around the world on innovative approaches to leprosy elimination. Leprosy is now part of the Novartis Global Health & Corporate Responsibility Unit as a Flagship program. Novartis Global Health & Corporate Responsibility aims to transform health in lower income populations through applying expertise, people and full organizational capability to address major, unresolved global health challenges.

ADVERTISEMENT
Previous Post

Increased per passenger ancillary revenue offers hope for Wizz Air, says GlobalData

Next Post

Thabiso Romosolo: Education is the key to possibilities

Press Room

Press Room

Nomad Africa celebrates life on the African continent. Covering stories from all countries and all cultures, it strives to include unique tourist attractions, business development, technology and investment opportunities as well as looking at the continent's cultural heritage.

Related Posts

Vodacom Nomad Mpesa
News

Vodacom Launches M-Pesa Rallonge in Partnership with Access Bank

December 11, 2022
Emerson Mnangagwa Nomad
News

“Private Sector Opportunities in Zimbabwe are Limitless” – Zimbabwe President Dr. Emerson Mnangagwa

November 5, 2022
MORE Field Guide College Opens Second Campus in the Greater Kruger Region
News

MORE Field Guide College Opens Second Campus in the Greater Kruger Region

August 28, 2022
Next Post
Thabiso Romosolo: Education is the key to possibilities

Thabiso Romosolo: Education is the key to possibilities

Please login to join discussion

Search This Website

No Result
View All Result

ADVERTISEMENT

Recent Posts

  • Going Big: Here Are The Best Places to see the Big Five in Africa
  • Airlines Cut Losses in 2022; Return to Profit in 2023
  • Loadshedding in South Africa Accelerates the Return of Face-to-Face Meeting
  • Here Are Corporate Travel Trends That Will Shape The Future
  • My 3 Weeks Fabulous Experience In Paradise
  • Check Out the World’s Best Christmas Market
  • IATA Establishes Modern Airline Retailing Program
  • ‘Ready to Fly’ is Closer to Reality with New Industry Standards
  • Vodacom Launches M-Pesa Rallonge in Partnership with Access Bank
  • China: Losing its ‘Factory of the World’ Crown to India?
  • Arabian Travel Market 2023 to Make Net Zero Pledge
  • Here Are Six Ways to Make the Most of Your Mini-Break
  • SunSquare Cape Town Gardens: First Pet-Friendly Hotel?
  • Erinvale Estate Hotel & Spa Receives Five-Star Grading
  • Delta Launches Nonstop Service From Cape Town to Atlanta

Trending on NomadTV

https://www.youtube.com/watch?v=e2bhBUqVHDw&t=3s

Tags

Africa African Cultural Sites African Tourism African Tribes Africa Travel Aviation Bucket list Business Tourism Business Travel Cape Town Covid-19 Covid19 Culture Domestic Tourism Energy eswatini Exclusive Exclusive Interview Existence Hotels Johannesburg Kenya Mauritius News Nigeria Rwanda Showcase South Africa South African Tourism Industry swaziland Tanzania Top Destination Top Ten Tourism Tourism Africa Tourism News Tourism Recovery Travel Travel News Travel Tech Travel Tips Travel Trends Uganda Zambia Zimbabwe

ADVERTISEMENT

ADVERTISEMENT
  • The Project
  • About Us
  • Advertise
  • Partner with us
  • Invest In Nomad
  • Donate
  • Get In Touch
Call us: +27.[0]10.590.6264, +27.719.130.776, +27.610.817.489 Email: info@nomadafricamag.com.
Send all press releases to editor@nomadafricamag.com.

© 2015 - 2022 All Rights Reserved 2414 Publishing (Pty) Ltd. Designed & Developed by: CreativeMagic Group.

No Result
View All Result
  • Home
  • Tourism News
  • Features
  • Top Destinations
  • Beliefs & Existence
  • Spotlight
  • Showcase
  • Get Published
  • Subscribe
  • Login

© 2015 - 2022 All Rights Reserved 2414 Publishing (Pty) Ltd. Designed & Developed by: CreativeMagic Group.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Wait! Have You Subscribed?

Subscribe to Nomad Africa today and never miss out on
travel and tourism updates across the continent of Africa. Get industry insights,
travel tips and understand how the latest trends will affect your business.
Get great member benefits, learn more about African culture and
support tourism in Africa. Subscription starts from only
R15 ($1 USD) per month. Cancel Anytime.

SUBSCRIBE NOW

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
en English
af Afrikaansar Arabicbg Bulgarianny Chichewazh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchen Englishtl Filipinofi Finnishfr Frenchde Germanel Greekha Hausahaw Hawaiianiw Hebrewhi Hindiig Igboid Indonesianga Irishit Italianja Japaneseko Koreanla Latinlt Lithuanianms Malaypl Polishpt Portuguesepa Punjabiru Russianst Sesothosn Shonasl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesexh Xhosayo Yorubazu Zulu

Add New Playlist